# Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery

> **NCT05300555** · PHASE4 · UNKNOWN · sponsor: **University of Sao Paulo General Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Atrial Fibrillation New Onset

## Interventions

- **DRUG:** Rivaroxaban 20 MG Oral Tablet
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT05300555
- **Lead sponsor:** University of Sao Paulo General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-05
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05300555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05300555, "Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05300555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*